首页> 外国专利> Pharmaceutical compositions for the treatment of Chronic Heart Failure comprising propyloxy - 5 - 2 - (5 - 1 - methyl - 2 - pirrolidinil Ethyl amidosulfonil) phenyl - 1 - methyl - 3 - propyl - 1.6 - dihydro 7h pyrazolo (4,3-d) pyrimidin-7-one

Pharmaceutical compositions for the treatment of Chronic Heart Failure comprising propyloxy - 5 - 2 - (5 - 1 - methyl - 2 - pirrolidinil Ethyl amidosulfonil) phenyl - 1 - methyl - 3 - propyl - 1.6 - dihydro 7h pyrazolo (4,3-d) pyrimidin-7-one

机译:用于治疗慢性心力衰竭的药物组合物,其包含丙氧基-5-[2-(5-1-甲基-2-吡咯烷腈乙酰胺基)苯基]-1-甲基-3-丙基-1.6-二氢7h吡唑并(4,3 -d)嘧啶7-7

摘要

1. - Pharmaceutical composition for the treatment of Chronic Heart Failure, which comprises a pirazolopirimidinona derivative represented by the following Chemical Formula 1, as an effective ingredient. Chemical formula 12.The pharmaceutical composition according to claim 1, characterized in that it Inhibits the Cardiac morphological changes in heart failure cronica.3. - the pharmaceutical composition according to claim 1, characterized in that it Inhibits the elongation of David Ad ventricular and ventricular Wall thickness change in heart failure cronica.4.Method to treat Chronic Heart Failure, characterized in that it comprises administering a pirazolopirimidinona derivative represented by the following Chemical Formula 1, to a patient in need of such treatment in a therapeutically effective amount. Chemical Formula 1
机译:1-用于治疗慢性心力衰竭的药物组合物,其包含由以下化学式1表示的吡唑并吡咯烷酮衍生物作为有效成分。化学式12.根据权利要求1的药物组合物,其特征在于它抑制心脏衰竭冠状动脉的心脏形态变化。3。 -根据权利要求1所述的药物组合物,其特征在于,其抑制心力衰竭患者的David Ad心室和心室壁厚度的变化。4.治疗慢性心力衰竭的方法,其特征在于,所述方法包括给予以下列化学式1,以治疗有效量给予需要这种治疗的患者。化学式1

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号